The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a gain of 40.12%.However, over the last six months, we can see a weaker performance of 94.67%. Over the last 30 days, the price of LCTX has fallen by 6.84%. And in the last five days, it has surged by 0.81%.
Lineage Cell Therapeutics Inc (LCTX) currently has a stock price of $1.25. The stock saw a sharp increase in the last trading session, hitting a high of $9.0 after opening at $1.25. The lowest recorded price for the day was $2.0 before it closed at $1.17.
Lineage Cell Therapeutics Inc had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $1.31 on 08/15/25, while the lowest price during the same period was $0.37 on 04/09/25.
52-week price history of LCTX Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Lineage Cell Therapeutics Inc’s current trading price is -4.58% away from its 52-week high, while its distance from the 52-week low is 242.37%. The stock’s price range for this period has been between $0.37 and $1.31. The Healthcare sector company’s shares saw a trading volume of about 2.31 million for the day, which was lower than the average daily volume of 2.48 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly rise of 83.04% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 285.45M and boasts a workforce of 77 employees.
Expert Opinions: Analysts’ Ratings for Lineage Cell Therapeutics Inc
As of right now, 3 analysts are rating Lineage Cell Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7810, with a change in price of +0.8128. Similarly, Lineage Cell Therapeutics Inc recorded 1,967,932 in trading volume during the last 100 days, posting a change of +185.91%.
LCTX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
As of today, the raw stochastic average of Lineage Cell Therapeutics Inc over the past 50 days is 88.35%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 83.52%. Additionally, the Stochastic %K and %D values for the company were 71.61% and 67.34%, respectively, over the past 20 days.
